Auxilium sells $325m in convertible debt to fund hedges and operations
This article was originally published in Scrip
Auxilium Pharmaceuticals is selling 1.5% convertible senior notes due in 2018 with an aggregate principal amount of $325 million for "general corporate purposes" and to pay the cost of note hedge transactions meant to protect investors from dilution and offset the company's cash payments associated with selling debt to finance its operations.
You may also be interested in...
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.